Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b study of SAR442970 in moderate to severe ulcerative colitis
jRCT2021250015Phase 2Recruiting
- Sponsor
- Sanofi
- Start
- Feb 2026
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial of brivekimig in autoimmune colitis (3 arms), sponsored by Sanofi. Primary endpoint: Clinical remission by modified Mayo Score at Week 16. Started Feb 2026; status: recruiting.
02
Drugs
brivekimig
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on jRCT2021250015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021250015.